GIA632
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
Atopic DermatitisAtopic dermatitisCutaneous Lichen PlanusNon-segmental VitiligoNonsegmental vitiligo
Phase 2
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Active, not recruitingNCT07220577
Start: 2025-11-10End: 2027-09-06Updated: 2026-05-14
A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis
Not yet recruitingCTIS2025-521503-43-00
Target: 52Updated: 2026-01-19
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RecruitingNCT07431177
Start: 2026-03-09End: 2030-01-28Target: 210Updated: 2026-09-09
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
Not yet recruitingCTIS2025-522301-37-00
Target: 59Updated: 2026-06-10
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
RecruitingNCT07775924
Start: 2026-09-10End: 2030-02-13Target: 259Updated: 2026-09-15